Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

Home/Biomarker

FGFR2 fusion / rearrangement

Gene: FGFR2 · Type: fusion

Indications: Cholangiocarcinoma

Sensitivity Resistance CIViC Context

Linked CIViC Profile: FGFR2 FUSION

Evidence Level Distribution

Level A: 1Level B: 3Level C: 2Level D: 2

Level	Type	Direction	Significance	Disease	Drugs	Rating
B	Predictive	Supports	Sensitivity/Response	Cholangiocarcinoma	Infigratinib	4
A	Predictive	Supports	Sensitivity/Response	Transitional Cell Carcinoma	Erdafitinib	4
D	Predictive	Supports	Sensitivity/Response	Endometrial Cancer	Ponatinib	3
D	Predictive	Supports	Sensitivity/Response	Endometrial Cancer	PD173074	3
B	Predictive	Supports	Sensitivity/Response	Stomach Carcinoma	Fexagratinib	3
C	Predictive	Supports	Sensitivity/Response	Head And Neck Squamous Cell Carcinoma	Pazopanib	3
B	Predictive	Supports	Sensitivity/Response	Breast Cancer	Dovitinib	2
C	Predictive	Supports	Sensitivity/Response	Cholangiocarcinoma	Infigratinib	2